Repaglinide does not induce or inhibit CYP3A4. Risk for gastrointestinal adverse events in the form of abdominal pain and diarrhoea motivates vigilance against insufficient intake of food, especially of carbohydrate.

Carbamoylmethyl benzoic acid derivative

Repaglinide is indicated for the treatment of diabetes type 2 as monotherapy or in combination with metformin. Common side effects that can be potentially porphyrinogenic through reduction in carbohydrate intake and that also can be confused with an acute porphyria attack are abdominal pain and diarrhoea.

Probably not significant

Repaglinide is metabolized mainly by CYP2C8 and to a smaller degree by CYP3A4 (SPC). Repaglinide was co-administrated with theophylline, a CYP3A4 substrate, and did not induce or inhibit theophylline (Hatorp 2000).